12:00 AM
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zybrestat fosbretabulin: Completed Phase II enrollment

OxiGene said the Gynecologic Oncology Group (GOG) completed enrollment of 110 patients in the open-label, U.S. Phase II GOG 186I trial comparing Zybrestat plus 15 mg/kg IV Avastin bevacizumab every 21 days vs. Avastin...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >